https://medhelp.org/user_journals/show/1739543 Medical communities and forums staffed by doctors from leading medical centers. Over 325 forums and communities providing medical information and medical help. en Below please find data from Phase II of the Interferon-free Cosmos study presented at EASL 2014 in Lo Advocate1955 Mon, 14 Apr 2014 06:14:51 -0400 https://medhelp.org/user_journals/show/1058321/EASL-2014-Final-Phase-II-data-from-Interferon-free-COSMOS-Study https://medhelp.org/user_journals/show/1058321/EASL-2014-Final-Phase-II-data-from-Interferon-free-COSMOS-Study Below is an article that came out on 4/12/14 in the New England Journal of Medicine summarizing resul Advocate1955 Sat, 12 Apr 2014 16:57:26 -0400 https://medhelp.org/user_journals/show/1057716/Ledipasvir-Sofosbuvir-94-99-SVR-rate-for-HCV-G1-previous-non-responders https://medhelp.org/user_journals/show/1057716/Ledipasvir-Sofosbuvir-94-99-SVR-rate-for-HCV-G1-previous-non-responders Below are two sections from the recently released AASLD and IDSA recommendations for testing, managin Advocate1955 Sun, 09 Feb 2014 11:27:07 -0500 https://medhelp.org/user_journals/show/1009539/Recommendations-for-Testing-Managing-and-Treating-Hepatitis-C-from-AASLD-and-IDSA https://medhelp.org/user_journals/show/1009539/Recommendations-for-Testing-Managing-and-Treating-Hepatitis-C-from-AASLD-and-IDSA My husband saw his hepatologist for a routine follow up (labs, imaging, check up) earlier this month Advocate1955 Thu, 26 Dec 2013 11:41:09 -0500 https://medhelp.org/user_journals/show/989565/Appointment-with-Hepatologist-on-12-5-13 https://medhelp.org/user_journals/show/989565/Appointment-with-Hepatologist-on-12-5-13 According to information presented at AASLD 2013 in Washington D.C., results of the LONESTAR study de Advocate1955 Thu, 28 Nov 2013 11:34:37 -0500 https://medhelp.org/user_journals/show/964210/AASLD-2013-sofosbuvir-ledipasvir-with-or-without-ribavirin https://medhelp.org/user_journals/show/964210/AASLD-2013-sofosbuvir-ledipasvir-with-or-without-ribavirin According to information presented at AASLD 2013 in Washington D.C. this month, results of the ELECTR Advocate1955 Thu, 28 Nov 2013 11:25:51 -0500 https://medhelp.org/user_journals/show/964209/AASLD-2013-sofosbuvir-ledispavir-plus-ribavirin-or-GS9669 https://medhelp.org/user_journals/show/964209/AASLD-2013-sofosbuvir-ledispavir-plus-ribavirin-or-GS9669 According to information presented at AASLD 2013 in Washington, D.C. this month, results of the Phase Advocate1955 Thu, 28 Nov 2013 11:04:00 -0500 https://medhelp.org/user_journals/show/964204/AASLD-2013-Simeprevir-Sofosbuvir https://medhelp.org/user_journals/show/964204/AASLD-2013-Simeprevir-Sofosbuvir AbbVie reported results of a trial involving a 12 week regimen of 3 drugs combined with RBV trials (9 Advocate1955 Sun, 28 Apr 2013 14:09:52 -0400 https://medhelp.org/user_journals/show/751088/EASL-2013-International-Liver-Conference-AbbVie https://medhelp.org/user_journals/show/751088/EASL-2013-International-Liver-Conference-AbbVie Janssen R & D (Ireland) reported results of two Phase 3 trials, G1 & G2, treatment naive, simeprevir. Advocate1955 Sun, 28 Apr 2013 14:04:00 -0400 https://medhelp.org/user_journals/show/751085/EASL-2013-International-Liver-Conference-Janssen https://medhelp.org/user_journals/show/751085/EASL-2013-International-Liver-Conference-Janssen Boehringer Ingelheim reported results of one Phase 3 trial, STARTVerso at the EASL 2013 International Advocate1955 Sun, 28 Apr 2013 13:59:48 -0400 https://medhelp.org/user_journals/show/751083/EASL-2013-International-Liver-Conference-Boehringer-Ingelheim https://medhelp.org/user_journals/show/751083/EASL-2013-International-Liver-Conference-Boehringer-Ingelheim Gilead reported results on four phase 3 trials with sofosbuvir at EASL 2013, International Liver Conf Advocate1955 Sun, 28 Apr 2013 13:54:50 -0400 https://medhelp.org/user_journals/show/751082/EASL-2013-International-Liver-Conference-Gilead https://medhelp.org/user_journals/show/751082/EASL-2013-International-Liver-Conference-Gilead Copyman, another member of this forum, posted this link to a Hep C Survival Guide a couple of days ag Advocate1955 Wed, 26 Dec 2012 12:01:42 -0500 https://medhelp.org/user_journals/show/634676/Link-to-Hep-C-Survival-Guide https://medhelp.org/user_journals/show/634676/Link-to-Hep-C-Survival-Guide Thank you to mikesimon for sharing this article. I am posting it in my journal for reference. Advoc Advocate1955 Wed, 19 Dec 2012 07:45:31 -0500 https://medhelp.org/user_journals/show/628735/Regular-marijuana-use-increases-risk-of-Hep-C-related-liver-damage https://medhelp.org/user_journals/show/628735/Regular-marijuana-use-increases-risk-of-Hep-C-related-liver-damage Here is a copy of a list that Orphaned Hawk posted in her journal and a list that Hector SF posted Advocate1955 Wed, 05 Dec 2012 07:55:20 -0500 https://medhelp.org/user_journals/show/615811/Preparing-for-first-appointment-with-hepatologist https://medhelp.org/user_journals/show/615811/Preparing-for-first-appointment-with-hepatologist Saw hepatologist last week. News is good. Liver is compensated, no sign of cancer, labs good. CT Advocate1955 Sat, 01 Dec 2012 15:03:56 -0500 https://medhelp.org/user_journals/show/610936/Follow-up-with-Hepatologist-Nov-2012 https://medhelp.org/user_journals/show/610936/Follow-up-with-Hepatologist-Nov-2012 Bristol-Myers Squibb Company (BMS) announced yesterday at the Liver Meeting in Boston, Nov. 2012, tha Advocate1955 Mon, 12 Nov 2012 09:00:14 -0500 https://medhelp.org/user_journals/show/588318/Bristol-Myers-Squibb-Co-Phase-2-Data-Asunaprevir-Daclatasvir-up-to-78-SVR-rate-in-G1b-previous-null-responders https://medhelp.org/user_journals/show/588318/Bristol-Myers-Squibb-Co-Phase-2-Data-Asunaprevir-Daclatasvir-up-to-78-SVR-rate-in-G1b-previous-null-responders This information has already been posted on the Hep C forum, but I wanted to post it in my journals f Advocate1955 Sun, 11 Nov 2012 12:18:00 -0500 https://medhelp.org/user_journals/show/587516/Abbotts-triple-DAA-regimen-plus-Ribavirin-12-weeks-high-rates-of-SVR-in-both-treatment-naive-and-null-responders https://medhelp.org/user_journals/show/587516/Abbotts-triple-DAA-regimen-plus-Ribavirin-12-weeks-high-rates-of-SVR-in-both-treatment-naive-and-null-responders Boehringer Ingelheim (BI) announced that faldaprevir (BI201335) and BI207127 combined with Ribavirin Advocate1955 Sun, 11 Nov 2012 11:36:00 -0500 https://medhelp.org/user_journals/show/587498/Boehringer-Ingelheims-faldaprevir-BI201335-up-to-85-SVR-in-treatment-naive https://medhelp.org/user_journals/show/587498/Boehringer-Ingelheims-faldaprevir-BI201335-up-to-85-SVR-in-treatment-naive Merck announced that 96% of trial patients achieved SVR12 with it's protease inhibitor (MK-5172) comb Advocate1955 Sun, 11 Nov 2012 11:09:29 -0500 https://medhelp.org/user_journals/show/587495/Mercks-MK-5172-Phase-2-study-protease-inhibitor-96-SVR12 https://medhelp.org/user_journals/show/587495/Mercks-MK-5172-Phase-2-study-protease-inhibitor-96-SVR12 This has already been posted by Orphaned Hawk on the Hep C forum, but I thought it might be a good id Advocate1955 Sun, 11 Nov 2012 11:00:53 -0500 https://medhelp.org/user_journals/show/587492/Gileads-Sofosbuvir-GS-7977-100-SVR4-in-treatment-naive-G1s https://medhelp.org/user_journals/show/587492/Gileads-Sofosbuvir-GS-7977-100-SVR4-in-treatment-naive-G1s